ダラツムマブ
参考資料

↑  “KEGG DRUG: ダラツムマブ”. www.kegg.jp. 2021年10月6日閲覧。
↑  World Health Organization (2009). “International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 101”. WHO Drug Information 23 (2). http://whqlibdoc.who.int/druginfo/23_2_2009_INN101.pdf.
1 2  “Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma”. The New England Journal of Medicine 373 (13):  1207–19. (September 2015). doi:10.1056/NEJMoa1506348. hdl:1874/331934. PMID 26308596.
↑  “Archived copy”. 2017年1月13日時点のオリジナルよりアーカイブ。2017年1月10日閲覧。
1 2  “ダラザレックス点滴静注100mg／ダラザレックス点滴静注400mg 添付文書”. www.info.pmda.go.jp. 2021年10月6日閲覧。
1 2  “Daratumumab (Professional Patient Advice)” (英語). Drugs.com. 2021年10月6日閲覧。
1 2 3 4 5  “SUMMARY OF PRODUCT CHARACTERISTICS”. www.ema.europa.eu. 2019年6月4日閲覧。
↑  “Infectious complications and NK cell depletion following daratumumab treatment of Multiple Myeloma”. PLOS One 14 (2):  e0211927. (2019). Bibcode: 2019PLoSO..1411927N. doi:10.1371/journal.pone.0211927. PMC 6374018. PMID 30759167. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6374018/.
↑  “Preemptive therapy for cytomegalovirus reactivation after daratumumab-containing treatment in patients with relapsed and refractory multiple myeloma”. Annals of Hematology 98 (8):  1999–2001. (2019). doi:10.1007/s00277-019-03645-7. PMID 30824957.
↑  “Evolving Role of Daratumumab: From Backbencher to Frontline Agent”. Clinical Lymphoma, Myeloma & Leukemia 20 (9):  572–587. (2020). doi:10.1016/j.clml.2020.03.010. PMID 32331971.
↑  “Resolving the daratumumab interference with blood compatibility testing”. Transfusion 55 (6 Pt 2):  1545–54. (June 2015). doi:10.1111/trf.13069. PMID 25764134.
↑  Perincheri, Sudhir; Torres, Richard; Tormey, Christopher A.; Smith, Brian R.; Rinder, Henry M.; Siddon, Alexa J. (2016-12-02). “Daratumumab Interferes with Flow Cytometric Evaluation of Multiple Myeloma”. Blood 128 (22):  5630. doi:10.1182/blood.V128.22.5630.5630. ISSN 0006-4971.
↑  Dhillon S (2020). “Isatuximab: First Approval”. Drugs 80 (9):  905–912. doi:10.1007/s40265-020-01311-1. PMID 32347476.
1 2  “The Good, the Bad and the Unknown of CD38 in the Metabolic Microenvironment and Immune Cell Functionality of Solid Tumors”. Cells 9 (1):  52. (2019). doi:10.3390/cells9010052. PMC 7016859. PMID 31878283. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7016859/.
↑  “CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond”. International Journal of Molecular Sciences 21 (11):  4129. (2020). doi:10.3390/ijms21114129. PMC 7312896. PMID 32531894. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7312896/.
1 2  “Daratumumab - Janssen Biotech - AdisInsight”. adisinsight.springer.com. 2021年10月6日閲覧。
↑  Mistry, Jayna J; Moore, Jamie A; Kumar, Prakritt; Marlein, Christopher R; Hellmich, Charlotte; Pillinger, Genevra; Jibril, Aisha; Di Palma, Federica et al. (19 March 2020). “Daratumumab inhibits acute myeloid leukaemia metabolic capacity by blocking mitochondrial transfer from mesenchymal stromal cells”. Haematologica 106 (2):  589–592. doi:10.3324/haematol.2019.242974. PMC 7849566. PMID 32193250. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7849566/.
1 2  “Therapeutic Opportunities with Pharmacological Inhibition of CD38 with Isatuximab”. Cells 8 (12):  1522. (2019). doi:10.3390/cells8121522. PMC 6953105. PMID 31779273. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6953105/.
↑  “Daratumumab in multiple myeloma”. Cancer 125 (14):  2364–2382. (2019). doi:10.1002/cncr.32065. PMID 30951198.
↑  “Resistance Mechanisms Towards CD38-Directed Antibody Therapy in Multiple Myeloma”. Journal of Clinical Medicine 9 (4):  1195. (2020). doi:10.3390/jcm9041195. PMC 7230744. PMID 32331242. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7230744/.
↑  “ASCO: Drug Shows Promise in Myeloma”. MedPage Today. http://www.medpagetoday.com/HematologyOncology/Myeloma/33115
↑  “Daratumumab Continues To Show Promise For Relapsed/Refractory Myeloma Patients (ASH 2012)”. The Myeloma Beacon. http://www.myelomabeacon.com/news/2013/01/09/daratumumab-for-relapsed-refractory-myeloma-patients-ash-2012/ 2013年1月31日閲覧。
↑  “Daratumumab, lenalidomide, and dexamethasone for multiple myeloma”. New England Journal of Medicine 375 (14):  1319–1331. (2016). doi:10.1056/NEJMoa1607751. PMID 27705267.
↑  “Daratumumab, bortezomib, and dexamethasone for multiple myeloma”. New England Journal of Medicine 375 (8):  754–766. (2016). doi:10.1056/NEJMoa1606038. PMID 27557302.
↑  “Daratumumab Approved for Multiple Myeloma in US”. Medscape. 2021年10月6日閲覧。
↑  “Janssen's Single-Agent Darzalex (daratumumab) Approved by European Commission for Treatment of Multiple Myeloma (MM)” (23 May 2016). 2016年5月23日閲覧。
↑  “An overview of Darzalex and why it is authorised in the EU”. www.ema.europa.eu (2018年). 2019年6月4日閲覧。
↑  “Daratumumab (Darzalex)”. U.S. Food and Drug Administration (FDA) (9 February 2019). 2021年10月6日閲覧。
↑  “FDA approves Darzalex for newly diagnosed, transplant-ineligible multiple myeloma”. www.healio.com. 2018年5月8日閲覧。
↑  “ヒト抗CD38モノクローナル抗体ダラザレックス®点滴静注』 製造販売承認を取得”. Janssen Pharmaceutical K.K.. 2021年10月6日閲覧。
↑  “未治療の「多発性骨髄腫」に対する 『ダラザレックス®』の適応追加承認を取得”. Janssen Pharmaceutical K.K.. 2021年10月6日閲覧。